References
- Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet 2012;380:848-857. https://doi.org/10.1016/S0140-6736(12)60605-9
- Jung KW, Won YJ, Oh CM, Kong HJ, Cho H, Lee JK, et al. Prediction of cancer incidence and mortality in Korea, 2016. Cancer Res Treat 2016;48:451-457. https://doi.org/10.4143/crt.2016.092
- Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010;11:827-834. https://doi.org/10.1016/S1470-2045(10)70167-4
- Micallef IN, Remstein ED, Ansell SM, Colgan JP, Inwards DJ, Johnston PB, et al. The International Prognostic Index predicts outcome after histological transformation of low-grade non- Hodgkin lymphoma. Leuk Lymphoma 2006;47:1794-1799. https://doi.org/10.1080/10428190600757894
- Rossi G, Donisi A, Casari S, Re A, Cadeo G, Carosi G. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma. Cancer 1999;86:2391-2397. https://doi.org/10.1002/(SICI)1097-0142(19991201)86:11<2391::AID-CNCR29>3.0.CO;2-0
- Khatri VP, Caligiuri MA. A review of the association between interleukin-10 and human B-cell malignancies. Cancer Immunol Immunother 1998;46:239-244. https://doi.org/10.1007/s002620050483
- Domingo-Domenech E, Benavente Y, Gonzalez-Barca E, Montalban C, Guma J, Bosch R, et al. Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms. Haematologica 2007;92:1475-1481. https://doi.org/10.3324/haematol.11350
- Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997;24:1-8. https://doi.org/10.1111/j.1365-2370.1997.tb00001.x
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer, 2008.
- Warnes G, Gorjanc G, Leisch F, Man M. 2013. Genetics: a package for population genetics. R Package (Version 1.3.8.1). R Foundation. Accessed 2016 Oct 1. Available from: http://www.r-project.org.
- Zhang Y, Xia ZG, Zhu JH, Chen MB, Wang TM, Shen WX, et al. Association of interleukin-10 -3575T>A and -1082A>G polymorphisms with non-Hodgkin lymphoma susceptibility: a comprehensive review and meta-analysis. Mol Genet Genomics 2015;290:2063-2073. https://doi.org/10.1007/s00438-015-1058-y
- Li G, Li D. Relationship between IL-10 gene polymorphisms and the risk of non-Hodgkin lymphoma: A meta-analysis. Hum Immunol 2016;77:418-425. https://doi.org/10.1016/j.humimm.2016.03.006
- Dai ZM, He AL, Zhang WG, Liu J, Cao XM, Chen YX, et al. Association of the four common polymorphisms in interleukin-10 (rs1800890, rs1800896, rs1800871, and rs1800872) with non-Hodgkin's lymphoma risk: a meta-analysis. Int J Clin Exp Med 2014;7:4720-4733.
- Lee JJ, Kim DH, Lee NY, Sohn SK, Kim JG, Kim HJ, et al. Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol 2007;137: 329-336. https://doi.org/10.1111/j.1365-2141.2007.06570.x
- Bogunia-Kubik K, Mazur G, Wrobel T, Kuliczkowski K, Lange A. Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin's lymphoma. Tissue Antigens 2008; 71:146-150. https://doi.org/10.1111/j.1399-0039.2007.00984.x
- Kube D, Hua TD, Kloss M, Kulle B, Brockmoller J, Wojnowski L, et al. The interleukin-10 gene promoter polymorphism -1087AG does not correlate with clinical outcome in non-Hodgkin's lymphoma. Genes Immun 2007;8:164-167. https://doi.org/10.1038/sj.gene.6364364